Results 31 to 40 of about 82,604 (202)

A Rare p.T599dup BRAF Mutant NSCLC in a Non-Smoker

Current Oncology, 2020
V-RAF murine sarcoma viral oncogene homolog B1 (BRAF) mutated non-small-cell lung cancer (NSCLC) is an exceptionally rare form of lung cancer, found only in one to two percent of patients with an NSCLC diagnosis.
Alla Turshudzhyan, James Vredenburgh
doaj   +1 more source

Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction [PDF]

, 2018
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
Bye, Alex P., Donaghy, Dillon, Gibbins, Jonathan M., Kriek, Neline, Osborne, Ashley A., Sage, Tanya, Unsworth, Amanda J.   +6 more
core   +4 more sources

BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective

Frontiers in Oncology, 2022
V-Raf murine sarcoma viral oncogene homolog B (BRAF) kinase, which was encoded by BRAF gene, plays critical roles in cell signaling, growth, and survival. Mutations in BRAF gene will lead to cancer development and progression.
Ningning Yan, Sanxing Guo, Huixian Zhang, Ziheng Zhang, Shujing Shen, Xingya Li   +5 more
doaj   +1 more source

BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors

Frontiers in Oncology, 2022
Single agent and combination therapy with BRAF V600E/K and MEK inhibitors have remarkable efficacy against melanoma tumors with activating BRAF mutations, but in most cases BRAF inhibitor (BRAFi) resistance eventually develops.
Sean A. Misek, Bardees M. Foda, Bardees M. Foda, Thomas S. Dexheimer, Maisah Akram, Susan E. Conrad, Jens C. Schmidt, Jens C. Schmidt, Richard R. Neubig, Richard R. Neubig, Kathleen A. Gallo   +10 more
openaire   +3 more sources

Medical debulking with BRAF/MEK inhibitors in aggressive BRAF-mutant craniopharyngioma [PDF]

Neuro-Oncology Advances, 2020
BRAF-activating mutations have been detected in nearly all craniopharyngiomas of the papillary subtype, with interesting implications for patients with suboptimal tumor control. Here we report that combined treatment with BRAF and MEK inhibitors resulted in major clinical benefit in the case of a patient with a BRAF V600E-mutant papillary ...
Di Stefano, Anna Luisa, Guyon, David, Sejean, Karine, Feuvret, Loic, Villa, Chiara, Berzero, Giulia, Desforges Bullet, Virginie, Halimi, Emmanuel, Boulin, Anne, Baussart, Bertrand, Gaillard, Stephan   +10 more
openaire   +4 more sources

Treatment patterns of melanoma by BRAF mutation status in the USA from 2011 to 2017: a retrospective cohort study

Melanoma Management, 2019
Aim: To describe treatment changes from 2011 to 2017 and demographic/clinical characteristics of patients with advanced melanoma who received systemic therapy by BRAF status.
Shweta Shah, Leon Raskin, David Cohan, Omid Hamid, Morganna L Freeman   +4 more
doaj   +1 more source

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma [PDF]

Cancer Medicine, 2016
AbstractDespite major advances in the treatment of metastatic melanoma, treatment failure is still inevitable in most cases. Manipulation of key epigenetic regulators, including inhibition of Bromodomain and extra‐terminal domain (BET) family members impairs cell proliferation in vitro and tumor growth in vivo in different cancers, including melanoma ...
Paoluzzi, Luca, Hanniford, Douglas, Sokolova, Elena, Osman, Iman, Darvishian, Farbod, Wang, Jinhua, Bradner, James E., Hernando, Eva   +7 more
openaire   +2 more sources

Efficacy of BRAF Inhibitors in Asian Metastatic Melanoma Patients: Potential Implications of Genomic Sequencing in BRAF-Mutated Melanoma

Translational Oncology, 2016
BACKGROUND: The BRAF inhibitors vemurafenib and dabrafenib are currently the standard treatment for metastatic melanoma with BRAF V600 mutations. However, given the rarity of noncutaneous melanoma, including acral and mucosal subtypes, the efficacy of ...
Hee Kyung Kim, Sunyoung Lee, Kyung Kim, Mi Hwa Heo, Hansang Lee, Jinhyun Cho, Nayoung K.D. Kim, Woongyang Park, Su Jin Lee, Jung Han Kim, Kee-Taek Jang, Sang-Hee Choi, Jeeyun Lee   +12 more
doaj   +1 more source

Bilateral multifocal central serous retinopathy due to management of metastatic melanoma with BRAf MEK inhibitors: Case report

Current Problems in Cancer: Case Reports, 2023
Central serous retinopathy (CSR) is a lesser-established ocular toxicity associated with BRAF/MEK inhibitors, a targeted treatment used in BRAF-mutated melanoma.
Grisma Patel, Monisha Edirisooriya, Moloy Dey, Rosemeen Parkar   +3 more
doaj   +1 more source

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]

, 2018
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John, Hertel, Nadine, Johnson, Helen, Lee, Dawn, Meng, Yang, Morais, Edith, Philips, Zoe, Roskell, Neil, Walker, Andrew   +8 more
core   +1 more source